Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Source: 
Pharmaforum
News Tags: 
snippet: 

Fuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big biopharma companies, and Amgen is no exception.

The US biotech has just agreed a $2.7 billion deal with BeiGene that will give it a rapid route to rolling out its cancer drugs in China – both approved and in the development pipeline – as it tries to capture a bigger slice of a market expected to approach a value of $145-$175 billion by 2022.